News

Florence , May 2025 – X-ZELL is proud to announce the new Cryophore™ range of standardized multiplex antibody panels, developed in close collaboration with leading experts and WHO guideline authors from Europe and the United States. X-ZELL Founder & CEO, Dr...

Halle, November 2024 – The 2024 Seminar on Clinical Cytology in Pulmonology in Halle, Germany, made history by featuring Cryoimmunostaining™ in the official scientific program for the first time. The groundbreaking session marked a significant milestone in advancing...

Leipzig, July 2024 – New research from Germany has shown that X-ZELL technology could dramatically reduce the number of inconclusive cancer diagnoses from minimally invasive sample material. During a lecture given at the 45th European Congress of Cytology (ECC) in...

Leipzig, June 2024 –To celebrate the 45th anniversary of the European Congress of Cytology (ECC) in Leipzig, Germany, X-ZELL has launched the company’s inaugural Global Technology Trial. X-ZELL Founder & CEO, Dr Sebastian Bhakdi, unveiled the new partnership...

Singapore, March 2024 – X-ZELL is proud to announce that the company’s ground-breaking Next-Generation Cytology (NGC) technology is now officially available for routine use in Europe and the US. X-ZELL NGC is a platform technology combining next-generation...

Singapore, November 2023 – X-ZELL’s first global conference tour has officially wrapped after the series’ final instalment at the Annual Scientific Meeting of the American Society of Cytopathology (ASC) in Austin, Texas, USA. Aimed at promoting X-ZELL’s Next...

Budapest, October 2023 – New research has shown that X-ZELL Cryoimmunostaining™ is able to facilitate same-day cancer diagnoses from minimally invasive samples in routine clinical practice PD Dr. med. Achim Battmann, MD, PhD, chief pathologist at MVZ Frankfurt, a...

Singapore, September 2023 – A research team at Duke-NUS Medical School in Singapore has developed a T cell therapy that could play an important role in treating cancer recurrences after liver transplants. The new treatment, called IDRA HBV-TCR*, is able to target and...

Frankfurt, June 2023 – X-ZELL, a pioneering company in the field of next-generation cytology, is proud to announce a strategic collaboration with the Medizinisches Versorgungszentrum für Pathologie, Zytodiagnostik und Molekularpathologie (MVZ) in Frankfurt, Germany, a...

Singapore, August 2022 – X-ZELL is proud to announce the appointment of Michael Tillmann as member of the company’s executive board. Drawing on more than 30 years of experience in the pharmaceutical and diagnostics industry, Mr Tillmann previously held the CEO...